乌司奴单抗治疗溃疡性结肠炎患者的症状缓解与生活质量有意义改善:INSPIRE和COMMAND随机研究的析因分析
该析因分析基于INSPIRE和COMMAND随机研究,评估乌司奴单抗(RZB)诱导和维持治疗对溃疡性结肠炎(UC)症状缓解及健康相关生活质量(HRQoL)的影响。12周诱导期RZB1200较安慰剂更多患者达到综合症状完全缓解(21.8% vs 9.5%,名义P≤0.001),52周维持期RZB180较撤药安慰剂亦更高(23.5% vs 14.2%,名义P≤0.05)。RZB较安慰剂改善了多个HRQoL结局的个体内有意义变化。
要点
- 诱导期第12周综合症状完全缓解率RZB1200为21.8%,安慰剂为9.5%(名义P≤0.001)。
- 维持期第52周综合症状完全缓解率RZB180为23.5%,RZB360为19.4%,撤药安慰剂为14.2%。
- RZB较安慰剂在诱导和维持期均改善了多个HRQoL结局的有意义变化。
核心结论
- 在UC患者中,RZB治疗较安慰剂改善了UC相关症状和HRQoL结局。
研究设计与样本
- INSPIRE和COMMAND随机研究的析因分析;12周诱导期患者随机接受静脉RZB 1200 mg或安慰剂,52周维持期诱导临床应答者再随机接受皮下RZB 180 mg、RZB 360 mg或安慰剂(RZB撤药)。
主要发现
- 第4周RZB较安慰剂改善症状结局(名义P≤0.001;腹痛、排便急迫、大便失禁名义P≤0.01),并持续至12周诱导期(P≤0.001;腹痛P≤0.01;大便失禁、睡眠中断名义P≤0.001)。
- 52周维持期RZB较安慰剂(RZB撤药)在症状结局上取得更大改善。
- 第12周诱导期综合症状完全缓解率RZB1200为21.8%,安慰剂为9.5%(名义P≤0.001)。
- 第52周维持期综合症状完全缓解率RZB180为23.5%,RZB360为19.4%,安慰剂(RZB撤药)为14.2%(名义P≤0.05和P=0.1358)。
- 第12周诱导期RZB较安慰剂改善HRQoL结局的MWPCs(名义P≤0.001;误工时间名义P=0.0033);第52周维持期RZB180较安慰剂改善HRQoL结局的MWPCs(名义P≤0.001;总体工作受损名义P≤0.01,误工时间名义P=0.3324,工作时受损名义P≤0.05),更多RZB360患者达到UC症状问卷、炎症性肠病问卷和36项简表调查躯体成分总结的MWPCs(均名义P≤0.05)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Patients with ulcerative colitis (UC) experience disruptive symptoms that can impair quality of life (QoL). This study examined the effect of risankizumab (RZB) induction and maintenance treatment on symptom resolution and health-related QoL (HRQoL) outcomes. METHODS: For the 12-week induction, patients were randomized to intravenous (IV) RZB 1,200 mg (RZB1200) or placebo (PBO). For the 52-week maintenance, clinical responders to induction were rerandomized to subcutaneous (SC) RZB 180 mg (RZB180), RZB 360 mg (RZB360), or PBO (RZB withdrawal). This post hoc analysis assessed individual and comprehensive resolution of UC-related symptoms and clinically meaningful within-person changes (MWPCs) for HRQoL outcomes. RESULTS: RZB improved symptomatic outcomes compared with PBO at week 4 (nominal P ≤ 0.001; abdominal pain, bowel urgency, fecal incontinence [nominal P ≤ 0.01]) through the 12-week induction ( P ≤ 0.001; abdominal pain [ P ≤ 0.01]; fecal incontinence, sleep interruption [nominal P ≤ 0.001]). Greater improvements were achieved with RZB compared with PBO (RZB withdrawal) for symptomatic outcomes through the 52-week maintenance. More patients treated with RZB achieved comprehensive symptom resolution (complete resolution of all 6 UC-related symptoms) compared with PBO at week 12 of induction (RZB1200, 21.8%; PBO, 9.5% [nominal P ≤ 0.001]) and week 52 of maintenance (RZB180, 23.5%; RZB360, 19.4%; PBO [RZB withdrawal], 14.2%; nominal P ≤ 0.05 and P = 0.1358, respectively). RZB compared with PBO improved MWPCs across HRQoL outcomes at week 12 of induction (nominal P ≤ 0.001; work time missed [nominal P = 0.0033]). At week 52 of maintenance, RZB180 compared with PBO (RZB withdrawal) improved MWPCs across HRQoL outcomes (nominal P ≤ 0.001; overall work impairment [nominal P ≤ 0.01], work time missed [nominal P = 0.3324], impairment while working [nominal P ≤ 0.05]) and more patients treated with RZB360 achieved MWPCs for the Ulcerative Colitis Symptom Questionnaire, Inflammatory Bowel Disease Questionnaire, and the 36-Item Short-Form Survey Physical Component Summary (all nominal P ≤ 0.05). DISCUSSION: RZB treatment improved UC-related symptoms and HRQoL outcomes compared with PBO in patients with UC.
引用
- Torres J, Panés J, Siegel CA, et al. Symptom Resolution and Meaningful Improvement in Quality of Life With Risankizumab in Patients With Ulcerative Colitis: Post Hoc Analysis of the Randomized INSPIRE and COMMAND Studies. Am J Gastroenterol. 2025. PMID: 40094309. doi:10.14309/ajg.0000000000003420
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。